17 results about "Thrombin time" patented technology

The invention discloses a low-molecular-weight heparin precise drug delivery decision system and method based on expert rules, and relates to the technical field of medical data intelligent processing, the system comprises a data acquisition module and an expert rule module, the expert rule module comprises a first rule subset, a second rule subset, a third rule subset and a fourth rule subset; the analysis module is used for analyzing the thrombin time data and the platelet counting data according to a second rule subset and a third rule subset in the expert rule module to obtain a bleeding risk assessment result; and the administration dosage determination module is used for calling corresponding dosage parameters from the expert rule module according to the weight grading result of the expert rule module and the bleeding risk assessment result of the analysis module, adjusting the dosage parameters and determining the administration dosage of the low-molecular heparin. According to the method, key physiological data such as the body weight, the thrombin time and the platelet counting of a patient are collected, and an expert rule base is introduced, so that accurate personalized adjustment of the dosage of the low-molecular-weight heparin is realized.

The invention belongs to the technical field of medical diagnosis, and particularly relates to a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscesses and interactive application. According to the invention, it is found that six indexes including serum uric acid (UA), thrombin time (TT), neutrophil absolute value (NEUT #), age (Age), fever (Fever) and erythrocyte sedimentation rate (ESR) are related to the type of the lumbar major muscle abscess, and a visual column diagram construction method for identifying and diagnosing suppurative and tuberculous lumbar major muscle abscess and interactive application are invented. And a first visual and quantifiable column diagram (Nomogram) prediction model for differential diagnosis of lumbar major muscle abscess is provided for the field. The technical problem that an abstract mathematical prediction model is converted into a visual graphic diagnosis tool which is intuitive in form and convenient to operate is solved, so that the visual graphic diagnosis tool can be separated from dependence on specific computing equipment, and clinical medical staff can quickly and accurately apply the visual graphic diagnosis tool on a diagnosis and treatment site conveniently.

The utility model relates to the technical field of medical instruments, and discloses a kit for measuring activated partial thrombin time, which comprises a box body, a hinge is fixedly connected to the upper surface of the box body, a box cover is rotatably connected to the outer wall of the hinge, a handle is fixedly connected to the upper surface of the box cover, a clamping block is fixedly connected to the outer wall of the box cover, and the clamping block is fixedly connected to the upper surface of the box body. A timer and a temperature controller are sequentially and fixedly connected to the outer wall of the box body, a hollow lock is fixedly connected to the outer wall of the box body, a buzzer is fixedly connected to one side of the outer wall of the box body, germicidal lamps are fixedly connected to the two sides of the inner wall of the box body, and anti-impact sponge is fixedly connected to the inner wall of the box body. According to the utility model, the timer and the clamping component are matched with each other, so that the problems that errors are easy to occur due to the fact that manual time comparison is needed during measurement and the test tube is easy to break due to the fact that a reagent bottle body cannot be fixed in the use process of the reagent test tube are solved, and the effects of improving the detection precision and guaranteeing the safety of the test tube are achieved.

The invention provides application of a blood coagulation four-item detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent in preparation of a diabetic microangiopathy detection kit and the kit, and relates to the technical field of medical biology. The research finds that the microangiopathy of the T2DM patient is obviously associated with the four blood coagulation items, the plasma D dimer and the AT-III level, and the four blood coagulation items, the plasma D dimer and the AT-III all cause independent influence factors of the microangiopathy, so that the risk of the microangiopathy of the T2DM patient can be predicted by detecting related indexes clinically; the clinical auxiliary diagnosis value is relatively high; further, prothrombin time detection results, activated partial thromboplastin time detection results, thrombin time detection results and fibrinogen detection results can be obtained on the basis of a four-item blood coagulation detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent; determining the risk of the diabetic microangiopathy according to at least one of a blood plasma D dimer detection result and an antithrombin III detection result.

The invention belongs to biomedical materials, and particularly relates to an antibacterial and anticoagulant coating material for a blood contact material and application of the antibacterial and anticoagulant coating material. The antibacterial and anticoagulant coating material comprises copper tetracarboxyl phenyl porphyrin loaded with an anticoagulant and water-soluble polysaccharide. A coating formed on the basis of the antibacterial and anticoagulant coating material can achieve antibacterial and anticoagulant effects at the same time, for example, the bacteriostasis rate on escherichia coli and the bacteriostasis rate on staphylococcus epidermidis can reach 90%; in addition, the activated part thromboplastin time, prothrombin time and thrombin time of the coating are obviously higher than those of an untreated blood contact material; and the hemolysis rate is lower than 5%.

The present invention relates to the field of biological preparations, and in particular to a thrombin time quality control product and a preparation method and application thereof. The present invention provides a thrombin time quality control product, the raw materials of which include blood, an anticoagulant and a freeze-dried protective solution, the prepared quality control product has good stability after reconstitution, the freeze-dried product has good long-term stability, and the freeze-dried product has stability of up to 33 months. In addition, the quality control material preparation process of the present invention is simple and low-cost, the raw materials are easily available, and it is suitable for mass production, and has good industrialization and clinical application prospects.

A thrombin solution, a kit, a method for stabilizing thrombin, a detection reagent, and a method for measuring thrombin time. The thrombin solution contains thrombin and contains an antifoaming agent. The thrombin solution has improved stability, enabling the thrombin to remain stable for a long time even at a low activity.

The invention belongs to the field of basic medicine, and particularly relates to a method for establishing a blood coagulation disorder animal model, which comprises the following steps of: performing intragastric administration on a healthy rat with a preparation containing podophyllotoxin according to the dose of 10mg / kg per day, and continuously performing administration for 4 days; wherein the drug administration can induce the rat to generate blood coagulation disorder phenotypes, and the phenotypes at least comprise prothrombin time prolonging, activated partial thromboplastin time prolonging and thrombin time prolonging. According to the establishment method of the blood coagulation disorder animal model, it is determined that podophyllotoxin can cause whole-body blood coagulation disorder, and the stable and repeatable blood coagulation disorder animal model is provided.

The application provides a camel milk casein anticoagulant peptide, a preparation method and application, and the camel milk casein anticoagulant peptide is ISQFYQKWK. The application takes camel milk casein as raw material, obtains the target anticoagulant peptide through enzymolysis, separation and identification and solid-phase synthesis, solves the problems that existing anticoagulant drugs have bleeding risk, are relatively high in cost and are limited in long-term application, and simultaneously improves the high-value utilization level of camel milk casein resources. The camel milk casein anticoagulant peptide is natural in origin, clear in sequence, has good in-vitro anticoagulant activity, can intervene in the blood clotting process by prolonging the activated partial thromboplastin time, the prothrombin time and the thrombin time.

The invention discloses an extraction and separation method of anise polysaccharide with anticoagulant activity. The method comprises the following steps: crushing fresh anise, extracting with hot water, concentrating a water extract, and adding ethanol for precipitation to obtain crude polysaccharide; removing protein by adopting a Sevage method; and dialyzing to remove small molecular impurities, and freeze-drying to obtain the purified anise polysaccharide. The molecular weight of the polysaccharide is about 72.053 kDa. In-vitro coagulation experiments show that the polysaccharide can significantly prolong prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) and reduce the content of fibroblast egg (FIB) white, and shows significant anticoagulant activity. The star anise polysaccharide provided by the invention can be used for preparing anticoagulant drugs, and has the advantages of wide raw material source, simple extraction process, definite activity and the like.

The present application relates to the field of machine learning, in particular to a blood sample classification method and system for coagulation index detection based on MAML and spatial transformation, mainly using a spatial transformation module to classify coagulation indexes, the specific steps comprising: obtaining the curve images of prothrombin time (PT) and thrombin time (TT) samples, extracting features and creating a training set and a test set; inputting the training set images into a module combining spatial transformation and convolution network to generate processed images; then updating parameters using gradient descent of the training model, reconstructing a spatial transformation coagulation index classification model; setting hyperparameters for the abnormal coagulation index classification model; finding the optimal model training process through model training and iterative testing to realize the classification of coagulation indexes. The present application uses MAML algorithm and spatial transformation to gradually optimize a small number of samples to achieve good generalization ability, and combines neural network structure and learning algorithm, which has wide applicability and flexibility.

This invention discloses the application of sodium thiocyanate in the preparation of a kit for coagulation assays. The kit detects coagulation parameters based on coagulation methods, chromogenic substrate methods, or immunoturbidimetric assays. These coagulation parameters include prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin(ogen) degradation products, D-dimer, antithrombin III, and anti-Xa. By adding sodium thiocyanate to the coagulation assay kit, this invention optimizes the clinical relevance of the assay kit by adjusting reaction time (coagulation method), improving the linear range (chromogenic substrate method), and enhancing the differentiation between low and high values ​​(immunoturbidimetric assay), thereby improving the accuracy of the test.

The invention discloses a prediction model for early warning of leukemia sepsis, and belongs to the technical field of medical information. Immunosuppression and infection of leukemia patients are rapidly deteriorated, and existing indexes and models are low in sensitivity and difficult to recognize sepsis in time. According to the system, eight conventional indexes, namely C reactive protein, procalcitonin, neutrophil counting, lymphocyte counting, thrombin time, red blood cell counting, total bile acid and systolic pressure, of the first day of admission are extracted, key features are screened through single-factor logistic regression, LASSO and Boruta algorithms in a combined mode, a random forest model is trained, and 10-fold cross validation and grid search optimization are conducted; a nonlinear relation is analyzed by combining SHAP explanation and a restrictive cubic spline, AUC0.765 is trained, AUC0.700 is verified, individualized risk scoring is provided, a hospital information system is embedded, clinical early intervention is guided, and death is reduced.

The present disclosure provides antibodies that bind to the catalytic domain of factor XI (FXI) and methods of use thereof. According to certain embodiments, the antibodies are antagonistic antibodies that inhibit clot formation via the intrinsic pathway without affecting hemostasis, as demonstrated by their ability to prolong aPTT without affecting PT. Thus, these antagonistic antibodies can be used in the treatment or therapeutic regimen of blood clotting diseases or disorders that have clot formation as a risk factor, such as, but not limited to, atrial fibrillation. In certain embodiments, the present disclosure includes antibodies that bind to FXI and mediate clot or thrombus formation. The antibodies of the present disclosure can be fully human, non-naturally occurring antibodies.

The invention relates to a clinical diagnosis model for early diagnosis of fever with thrombocytopenia syndrome (SFTS) complicated by acute pancreatitis (AP) and a construction method thereof. The model is constructed through Logistic regression analysis and LASSO regression analysis on the basis of indexes such as virus load (DBV RNA), thrombin time (TT), amylase (AMY) and blood calcium (Ca). The model shows good distinction degree and calibration degree in a training queue and a verification queue, can effectively predict the risk of concurrent AP of the SFTS patient, and has relatively high clinical practicability and prediction accuracy.

The invention relates to a thrombin time detection kit, and relates to the technical field of medical examination. The thrombin time detection kit comprises thrombin, mannitol, trisodium citrate, anhydrous sodium sulfate and a preservative. The measured values of normal plasma samples are not more than 20s, and the intra-batch precision (CV): the coefficient of variation (CV) of a normal quality control product and an abnormal quality control product is not more than 5%; the inter-batch precision (CV) is not higher than 10%; and the inter-bottle difference (CV) of the dry powder reagent is not higher than 8%. According to the detection kit, the content of the interfering substance hemoglobin is not higher than 800mg / dL, the content of the fat emulsion is not higher than 400mg / dL, and the content of the bilirubin is not higher than 20mg / dL, so that the detection kit can meet the requirements of clinical application and has relatively good clinical detection performance.

The invention belongs to the technical field of health-care tea, and particularly relates to radix astragali composite granular tea with an anticoagulation function and a preparation method of the radix astragali composite granular tea. According to the invention, twelve medicinal and edible Chinese herbal medicines such as radix astragali, radix salviae miltiorrhizae, pseudo-ginseng and the like are used as raw materials, and the health-care radix astragali composite granular tea is prepared through the technological processes of decoction, concentration, granulation, drying and the like. The radix astragali composite granular tea can significantly prolong activated partial thrombin time (APTT), prothrombin time (PT) and thrombin time (TT) (P is less than 0.05), and can play an anticoagulant role through an endogenous blood coagulation pathway, an exogenous blood coagulation pathway and a pathway of inhibiting fibrinogen from being converted into fibrin. The tea can meet the pursuit of people for nutrition, health care, convenience and rapidness, does not lose the flavor characteristics of granular tea, has a certain anticoagulation function, develops the research direction of health tea, and is wide in market prospect.